Practical use of hepatitis C virus kinetics monitoring in the treatment of chronic hepatitis C

Journal of Viral Hepatitis

Volumn 14, Issue SUPPL. 1, 2007, Pages 77-81

  Chevaliez, S ^b   Pawlotsky, J M ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b NONE

Author keywords

Hepatitis C virus; Real time polymerase chain reaction; Viral kinetics

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN; RNA;

ANTIVIRAL THERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KINETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; TREATMENT RESPONSE; VIROLOGY; VIRUS DETECTION;

HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS;

EID: 35448998881     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00923.x     Document Type: Conference Paper

References (22)

1. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002, June 10-12, 2002. Hepatology 2002 36 (5 Suppl. 1 S3 S20.
2. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998 282 (5386 103 107.
3. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005 25 (1 72 83.
4. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002 122 (6 1554 1568.
5. Komurian-Pradel F, Paranhos-Baccala G, Sodoyer M et al. Quantitation of HCV RNA using real-time PCR and fluorimetry. J Virol Methods 2001 95 (1-2 111 119.
6. Martell M, Gomez J, Esteban JI et al. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol 1999 37 (2 327 332.
7. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002 36 (5 Suppl. 1 S65 S73.
8. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007 46 (1 22 31.
9. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 (13 975 982.
10. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 (3 645 652.
11. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 351 (5 438 450.
12. Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004 351 (5 451 459.
13. Pawlotsky JM. Treating hepatitis C in "difficult-to-treat" patients. N Engl J Med 2004 351 (5 422 423.
14. Mangia A, Minerva N, Bacca D et al. In patients who clear HCV RNA at week 12, SVR is higher after 72 weeks than after 48 weeks treatment: results of a randomized controlled trial. Hepatology 2007 46 (1 S6.
15. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004 40 (6 1260 1265.
16. von Wagner M, Huber M, Berg T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005 129 (2 522 527.
17. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alpha-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007 357: 124 134.
18. Ferenci P, Bergholz U, Laferl H et al. 24 weeks treatment regimen with peginterferon alpha-2a (40 kDa) (Pegasys) plus ribavirin (Copegus) in HCV genotype 1 or 4 "super-responders". J Hepatol 2006 44 (2 S6.
19. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006 44 (1 97 103.
20. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006 43 (5 954 960.
21. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 130 (4 1086 1097.
22. Sanchez-Tapias JM, Diago M, Escartin P et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 131 (2 451 460.